MENLO PARK, Calif., March 31, 2017 /PRNewswire/ -- 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and metabolic diseases, announced today that it will present data from its ongoing Phase 1 clinical study of TVB-2640 in solid tumor patients at the AACR annual meeting in Washington, D.C. The abstract "First in human study of the first-in-class fatty acid synthase (FASN) inhibitor TVB-2640" has been selected for an oral presentation as part of a mini-symposium session titled "Novel Agent and Intervention Clinical Trials" on April 4, 2017 at 4:05PM local time. The Principal Investigator presenting details about the trial is Dr. Gerald Falchook from the Sarah Cannon Research Institute at HealthONE, Denver, CO.
"As the first-in-human study now nears completion, we are very encouraged by the safety of, and preliminary activity seen with TVB-2640 in this group of highly pre-treated patients. We are especially encouraged by the activity seen in KRAS mutant NSCLC, breast and ovarian cancers which will be described in more detail during the session at AACR", said Dr. Gerald Falchook. "We look forward to further development in Phase II studies, particularly given the poor prognosis and lack of effective therapies that target KRAS mutant NSCLC."
Presentation date: 4/4/2017
Presentation time: 4:05pm local time
Speaker: Dr. Gerald Falchook
About 3-V Biosciences
3-V Biosciences, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics in oncology and liver diseases based on expertise in lipid biology. The company's lead product candidate is a first-in-class inhibitor of fatty acid synthase (FASN) currently being evaluated in a Phase 1 clinical trial. Lipids are integral to cellular metabolism, cellular signaling and cellular structure and the emerging understanding of lipid biology opens up promising new areas for drug development. The company is located in Menlo Park, California.
Corporate Development & Finance
SOURCE 3-V Biosciences, Inc.